REVEAL BIOSCIENCES, INC.
SAN DIEGO, CA · Medtech · Acquired
imageDx: Prostate, an AI-enabled image analysis software that analyzes prostate cancer biopsy/surgical pathology images to predict patient risk for disease progression or recurrence
revealbio.com →- Grants
- $392K
- 1 award
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1916 | Scilex Pharmaceuticals Inc. | — | $7.5M |
| 1917 | Stratagen Bio, Inc. | — | — |
| 1918 | Osheru, Inc. | — | $5.0M |
| 1919 | REVEAL BIOSCIENCES, INC. | — | — |
| 1920 | WEARABLE ARTIFICIAL ORGANS, INC. | — | — |
| 1921 | STEADI SYSTEMS, LLC | — | — |
| 1922 | Innoventric | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.